Pinned Tweet
Ergo: The Best Blockchain You’ve Never Heard Of
Just because Ergo , $ERG, has a low market cap, is ignored by influencers, and remains relatively unknown doesn’t mean it isn’t the truest, best blockchain on the market. In fact, history shows that the most valuable technologies often start in obscurity while hype cycles chase fleeting trends.
Right now (or most of the time), the crypto market is driven by meme mania and short-term speculation. People pile into projects with no fundamentals, fueled by hype, only to get rugged when the inevitable crash happens. But cycles repeat, and after enough people get burned, real value wins.
Ergo isn’t just another blockchain—it’s one of the most advanced, well-designed, and resilient ecosystems in existence. With:
✅ True decentralization (no VCs, no premine, no insider control)
✅ Innovative eUTXO smart contracts (more secure and scalable than Ethereum’s account model)
✅ Advanced privacy and DeFi tools (Sigma protocols, ErgoMixer, etc.)
✅ A fair, long-term approach (no hype-driven pumps, just real tech)
⏱️ Sub Blocks coming soon…
The market can ignore Ergo for now, but it can’t ignore true innovation forever. When the dust settles and people look for blockchains that actually work—not just promises on a whitepaper—Ergo will be standing tall.
Value always finds its way home. Stay patient. Build. Accumulate. Experiment.
Wesley Capital retweeted
AI will make most software nearly free.
Except the kind where you have to beat someone.
A to-do app only has to work. A trading bot has to be better than the other bot.
That's the game we're building.
game-of-prompts.github.io
DNA medicine will develop at a rapid pace.
$INO
Btfd
It seems @coinexcom is selling users ERGs at the moment. The biggest liquidation in Ergo history!
Wesley Capital retweeted
It seems @coinexcom is selling users ERGs at the moment. The biggest liquidation in Ergo history!
Replying to @yhaiyang
$INO better late than never.
1st DNA medicine in USA and 22% short interest.
Just the beginning imo.
$XBI $PGEN
Inovio Pharmaceuticals- $INO
6 Month, All-Time Chart
HTF RSI Bullish Divergence
DNA Medicine and dMABs are coming fast once INO-3107 is brought to market.
Imagine a 1 shot GLP-1 dMAB, a breast cancer vaccine that stops cancer before it starts, and a HPV therapy that clears the virus from your body.
Wall Street knows money but I know science and patience…major revaluation coming soon.
$XBI $LABU $SPY
3
431
$INO 🧬
now.
1
185
Congratulations @InovioPharma on the first step towards a better future
DNA Medicine: The Future of Curing Diseases Beyond mRNA’s Reach
$INO v. $MRNA
Curing Long Term Disease:
DNA Medicine vs. mRNA Medicine
The past few years have seen rapid advancements in genetic medicine, with both DNA- and mRNA-based technologies revolutionizing how we approach disease treatment. While mRNA vaccines garnered widespread attention during the COVID-19 pandemic, DNA-based medicine may hold superior advantages in curing diseases, particularly for long-term and complex conditions.
Here’s why DNA medicine could outshine mRNA approaches in curing diseases:
1. Longer-Lasting Effects
DNA medicine works by delivering instructions to the cell’s nucleus, where it can generate a sustained and stable protein response. Unlike mRNA, which remains in the cytoplasm and is rapidly degraded, DNA therapies can maintain therapeutic effects for a longer period. This makes DNA medicine especially promising for chronic diseases or conditions requiring ongoing protein production.
2. Broader Applications
DNA medicine offers versatility beyond vaccines, including:
•Gene therapy to correct genetic defects directly.
•Immunotherapy for cancer by modifying immune cells to target tumors.
•Regenerative medicine to repair damaged tissues.
While mRNA is powerful for vaccines, its applications for gene correction and complex therapies are more limited.
3. Stability and Storage
DNA-based therapies are inherently more stable than mRNA at room temperature, reducing logistical challenges and costs associated with distribution. This is critical for scaling medical solutions in low-resource settings and ensuring equitable global access.
4. Lower Risk of Immune Overreaction
One challenge with mRNA medicines is the potential for strong immune system responses to the foreign RNA molecules. DNA therapies avoid this issue, as DNA does not provoke the same level of innate immune activation, making it safer in some cases.
5. Potential to Cure Diseases at Their Source
DNA medicine focuses on repairing or altering genetic blueprints, addressing diseases at their root cause. For example, DNA-based gene therapies hold the potential to permanently cure inherited disorders like sickle cell anemia or cystic fibrosis, whereas mRNA medicine often targets symptoms or provides temporary immunity.
6. Durability in Complex Diseases
DNA medicine could outperform mRNA in treating diseases like cancer or autoimmune conditions. Its ability to edit genes and sustain protein production over time makes it ideal for addressing diseases requiring long-term intervention, rather than just stimulating an immune response.
Challenges to Overcome
While DNA medicine offers exciting possibilities, it’s important to recognize its challenges, such as:
•Ensuring safe and precise delivery to target cells.
•Avoiding off-target effects during gene editing.
•Gaining regulatory approvals and proving clinical efficacy.
Conclusion
Both DNA and mRNA medicine have revolutionized science, but DNA medicine’s ability to correct genetic errors, provide sustained therapeutic effects, and offer versatile applications gives it a significant edge for curing complex and chronic diseases. While mRNA remains highly effective for short-term solutions like vaccines, the future of medicine will likely rely on DNA technologies to address the root causes of disease and transform how we think about cures.
The next few years will be pivotal in seeing how these technologies shape our healthcare landscape, but the promise of DNA medicine is undeniable.
$XBI
2
89
Long live DNA medicine 🧬
BREAKING NEWS: INOVIO has announced the FDA accelerated approval of its plasmid DNA-based immunotherapy to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (#RRP), a rare, debilitating HPV-related disease. The approval represents a major milestone for the RRP community and for INOVIO.
Read the full announcement here: bit.ly/approvalPR
Join a live webcast on Monday, November 2, to learn more about the approval: lnkd.in/eZJJ8wYG
45
Wesley Capital retweeted
BREAKING NEWS: INOVIO has announced the FDA accelerated approval of its plasmid DNA-based immunotherapy to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (#RRP), a rare, debilitating HPV-related disease. The approval represents a major milestone for the RRP community and for INOVIO.
Read the full announcement here: bit.ly/approvalPR
Join a live webcast on Monday, November 2, to learn more about the approval: lnkd.in/eZJJ8wYG
$INO DNA medicine is the future FYI
🧬 Inovio Pharmaceuticals $INO 🧬
$XBI
“Visual Evidence of Immunologic Clearance: INO-3107 in RRP”
Left (Pre-Treatment): Laryngeal papillomatosis with extensive HPV-6/11-driven lesions obstructing glottis and vocal folds.
Right (Year 1 Post-INO-3107): Complete macroscopic resolution — normal mucosal architecture restored.
Phase 1/2 (NCT04398433):
• 86% ORR at Year 2
• 50% Complete Response (0 surgeries)
• Median surgery reduction: 4.1 → 0.9/year
• Durability: >90% maintained ≥50% reduction at 2.8+ years
Mechanism: DNA-encoded HPV E6/E7 + IL-12 → antigen-specific CD8+ T-cell infiltration → targeted elimination of infected cells independent of tumor microenvironment.
BLA submitted Nov 3, 2025.
First DNA immunotherapy under FDA review.
This image is peer-reviewed proof (The Laryngoscope, 2025) that synthetic DNA can achieve durable viral clearance.
Platform implications: HPV cancers, chronic viruses, neoantigens.
I believe this to be a huge step forward in medicine.
Wesley Capital retweeted
🧬 Inovio Pharmaceuticals $INO 🧬
$XBI
“Visual Evidence of Immunologic Clearance: INO-3107 in RRP”
Left (Pre-Treatment): Laryngeal papillomatosis with extensive HPV-6/11-driven lesions obstructing glottis and vocal folds.
Right (Year 1 Post-INO-3107): Complete macroscopic resolution — normal mucosal architecture restored.
Phase 1/2 (NCT04398433):
• 86% ORR at Year 2
• 50% Complete Response (0 surgeries)
• Median surgery reduction: 4.1 → 0.9/year
• Durability: >90% maintained ≥50% reduction at 2.8+ years
Mechanism: DNA-encoded HPV E6/E7 + IL-12 → antigen-specific CD8+ T-cell infiltration → targeted elimination of infected cells independent of tumor microenvironment.
BLA submitted Nov 3, 2025.
First DNA immunotherapy under FDA review.
This image is peer-reviewed proof (The Laryngoscope, 2025) that synthetic DNA can achieve durable viral clearance.
Platform implications: HPV cancers, chronic viruses, neoantigens.
I believe this to be a huge step forward in medicine.
$INO onward.
BREAKING NEWS: INOVIO has announced the FDA accelerated approval of its plasmid DNA-based immunotherapy to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (#RRP), a rare, debilitating HPV-related disease. The approval represents a major milestone for the RRP community and for INOVIO.
Read the full announcement here: bit.ly/approvalPR
Join a live webcast on Monday, November 2, to learn more about the approval: lnkd.in/eZJJ8wYG
1
209
Wesley Capital retweeted
Ergo can not be shut down even by a state order as it is global GPU mineable proof of work blockchain based flat p2p network. And every piece of criticial infra around the chain is now massively replicated by the community.
Wesley Capital retweeted
The first mission of the Church is to help people be attentive to the profound questions of life: those concerning our origin and our destiny, as well as those concerning the meaning of love and suffering. The logic of profit at all costs and the manipulation of information risk exerting undue pressure on people to conform to a lifestyle centred on the consumption of material goods, but our hearts are made to look upwards. #GeneralAudience
Wesley Capital retweeted
$2B more to be dumped on retail in insider chains. And when retail cant buy anymore, most of those chains would just cease to exist like blast.
Chose fair game. Choose ergo:native
Tokens Worth Over $1.913B Face Major Unlocks Over the Next Month
According to Tokenomist, one-time unlocks exceeding $10 million over the next month include HYPE, BTW, ENA, ZRO, FF, XPL, APR, H, ARB, CARDS, SUI, CONX, and DBR. Linear unlocks exceeding $10 million per month include RAIN, SOL, CC, ZEC, TRUMP, WLD, ASTER, PUMP, AVAX, TAO, MORPHO, NEAR, STABLE, VVV, KITE, AERO, DOT, GRASS, and SN51. The total unlock value is expected to exceed $1.913 billion.
Wesley Capital retweeted
We are ready to give tools to produce better money with no state, for humans and AI agents, on any scale ergo:native
$META
LONG ZUCK
109























